药物基因组学和获得性尖端扭转室性心动过速  

Pharmacogenomics and acquired TdP

作　　者：洪葵[1] 李菊香[1] 程晓曙[1] 

机构地区：[1]南昌大学第二附属医院心内科江西省医学遗传和基因治疗研究所,南昌330005

出　　处：《临床心血管病杂志》2012年第3期161-162,共2页Journal of Clinical Cardiology

基　　金：国家重点基础研究发展计划973计划项目(No:2007CB512002);国家自然科学基金项目(No:81070148)

摘　　要：药物基因组学在心脏安全性方面的研究目的是了解与基因因素相关的安全性变量,开发有助于评估临床试验早期药物安全性的工具,防止易感患者不适当用药。随着华法林基因组学研究成果及"2010院内获得性尖端扭转室速(TdP)防治建议"的发表,临床医生对TdP的发生原因和防治措施有了比较清晰的了解。目前市面上大约存在50种因延长QT间期而有潜在诱导TdP危险的药物,本文据此重点阐述药物诱导TdP的遗传学、药代动力学及药效动力学,以为临床医生提供防治思路。The objective of pharmacogenomics study in cardiac is to find safety variables related to genetic factors,to develop tools that contribute to assess early drugs safety in clinical trials,and to prevent inappropriate medication in predisposing patients.With the warfarin genomics research and the 2010hospital acquired torsade de pointes（TdP）ventricular tachycardia prevention suggestions published,clinicians have a clear understanding about occurrence causes and control measures of TdP.There were about 50kinds of drugs in current market,and all have a potential risk of inducing TdP for extending QT interval.This review outlines expert opinions on phar-macokinetics,pharmacodynamics,and genetics of drugs-which induced TdP.

关 键 词：室性心动过速 尖端扭转 获得性 药物基因组学 药物安全性 

分 类 号：R541.7[医药卫生—心血管疾病]